A citation-based method for searching scientific literature

Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger, John K Chan, Susan A Davidson, Robert S Mannel, Paul A DiSilvestro, Heather A Lankes, Nilsa C Ramirez, Mary Claire King, Elizabeth M Swisher, Michael J Birrer. JAMA Oncol 2016
Times Cited: 331



Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley, Rebecca S Kristeleit, Ling Ma, Katherine M Bell-McGuinn, James D Brenton, Janiel M Cragun, Ana Oaknin, Isabelle Ray-Coquard, Maria I Harrell, Elaina Mann, Scott H Kaufmann, Anne Floquet, Alexandra Leary, Thomas C Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A McNeish. Lancet Oncol 2017
Times Cited: 530




List of shared articles



Times cited

Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.
Melanie Care, Jeanna McCuaig, Blaise Clarke, Sylvie Grenier, Raymond H Kim, Marjan Rouzbahman, Natalie Stickle, Marcus Bernardini, Tracy L Stockley. Mol Oncol 2021
3

The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Carolyn E Haunschild, Krishnansu S Tewari. Gynecol Oncol 2021
3

The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
Ciyu Yang, Angela G Arnold, Amanda Catchings, Vikas Rai, Zsofia K Stadler, Liying Zhang. Breast Cancer Res Treat 2021
0

Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Allison W Kurian, Kevin C Ward, Paul Abrahamse, Irina Bondarenko, Ann S Hamilton, Dennis Deapen, Monica Morrow, Jonathan S Berek, Timothy P Hofer, Steven J Katz. J Clin Oncol 2021
1

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, Cristina Correia, Taylor M Weiskittel, Rebecca L Kelly, Annapoorna Venkatachalam, Xiaonan Hou, Nicholas M Pathoulas, X Wei Meng,[...]. NAR Cancer 2021
0

Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Di Shao, Shaomin Cheng, Fengming Guo, Changbin Zhu, Yuying Yuan, Kunling Hu, Zhe Wang, Xuan Meng, Xin Jin, Yun Xiong,[...]. Cancer Sci 2020
6

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Soledad Jorge, Andrew S McFaddin, Kemi M Doll, Kathryn P Pennington, Barbara M Norquist, Robin L Bennett, Colin C Pritchard, Elizabeth M Swisher. Gynecol Oncol 2020
6

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Karen A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, Nicole N Boucicaut, Melissa Henson, Alexia Iasonos, Qin Zhou, Debra M Sarasohn, Jacqueline Gallagher, Sara Kravetz,[...]. Gynecol Oncol 2020
1

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N Grisham, Paul J Goodfellow, Elise C Kohn, Douglas A Levine, Joyce F Liu, Karen H Lu,[...]. J Clin Oncol 2020
41




Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Elizabeth K Lee, Ursula A Matulonis. Expert Opin Emerg Drugs 2020
1